We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Terns Pharmaceuticals Inc | NASDAQ:TERN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.14 | 2.33% | 6.14 | 5.99 | 6.26 | 6.33 | 5.86 | 5.98 | 774,422 | 22:59:00 |
TD Cowen 44th Annual Health Care ConferenceDate/Time: Monday, March 4, 2024 at 12:50 p.m. ETFormat: Panel PresentationLocation: Boston, MA
Inaugural BMO Obesity SummitDate/Time: Wednesday, March 20, 2024 at 11:00 a.m. ETFormat: Company PresentationLocation: New York, NY
Live webcasts of the events will be available on the investor relations page of Terns’ website at http://ir.ternspharma.com. A replay of the webcasts will be archived on Terns’ website for at least 30 days following the presentations.
About Terns PharmaceuticalsTerns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline includes three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, and a THR-β agonist, and a preclinical GIPR modulator program. For more information, please visit: www.ternspharma.com.
Contacts for Terns
InvestorsJustin Nginvestors@ternspharma.com
MediaJenna UrbanBerry & Company Public Relationsmedia@ternspharma.com
1 Year Terns Pharmaceuticals Chart |
1 Month Terns Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions